Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Enterprise Technology
  • Contract Manufacturing
  • R&D 100 Awards

Eli Lilly rises on Street-beating Q4

By Sean Whooley | January 29, 2021

Eli Lilly (NYSE:LLY) shares ticked up this morning on fourth-quarter results that beat the consensus forecast.

The Indianapolis-based company posted profits of $2.1 billion or $2.32 per share, on sales of $7.4 billion for the three months ended Dec. 31, 2020, for a 41.5% bottom-line gain on sales growth of 21.7%.

Adjusted to exclude one-time items, earnings per share were $2.75, 40¢ ahead of Wall Street, where analysts were looking for sales of $7.3 billion.

The company’s quarter included receiving FDA emergency use authorization (EUA) for both bamlanivimab and baricitinib (the latter for use in combination with remdesivir) in COVID-19 patients. Bamlanivimab, a COVID-19 antibody treatment, is for mild-to-moderate cases at risk of progresing to severe COVID-19, while baricitinib’s indication is for hospitalized patients who require supplemental oxygen, ventilation or extracorporeal membrane oxygenation.

“Lilly closed a complex year by delivering impressive results in the fourth quarter of 2020,” Eli Lilly chairman & CEO David A. Ricks said in a news release. “We finished the year with strong momentum in our core business areas, as volume-based revenue growth for our newest medicines and initial sales of our COVID-19 antibody therapy, coupled with our ongoing productivity agenda, drove robust margin expansion and solid earnings growth. I am also encouraged by exciting recent data readouts for three of our most important pipeline assets: tirzepatide, LOXO-305 and donanemab.

“Each of these potential medicines has a chance to significantly improve patient outcomes in areas of high unmet medical need, and, should they go on to receive approvals, reinforce our growth prospects for the decade ahead.”

Eli Lilly said it now expects to log adjusted EPS in the range of $7.75 to $8.40 for financial year 2021.

LLY shares were up 2.3% at $215 per share in early-morning trading today. MassDevice’s MedTech 100 Index — which includes stocks of the world’s largest medical device companies — was virtually unmoved.

Tell Us What You Think! Cancel reply

Related Articles Read More >

Becton Dickinson GSL Solutions
Becton Dickinson acquires smart medication device maker GSL Solutions
COVID-19 vaccine
How COVID-19 sidelined top vaccine manufacturers  
Pharmaceutical environment
Pharma’s been slow to adopt Industry 4.0 — but that could change
Johnson & Johnson Merck COVID-19 vaccine
Biden announces partnership for Merck to make J&J’s COVID-19 vaccine

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Pharmaceutical Processing news in a minute?

We Deliver!
Pharmaceutical Processing Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup

R&D Twitter

Tweets by @RandDWorld
Pharmaceutical Processing World
  • Enews Signup
  • Contact Us
  • About Us
  • R&D World
  • DeviceTalks
  • Drug Discovery & Development
  • Drug Delivery Business News
  • MassDevice
  • Medical Design Sourcing

Copyright © 2021 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Enterprise Technology
  • Contract Manufacturing
  • R&D 100 Awards